Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Waldencast plc - Class A Ordinary Share (NQ:WALD)

0.8746 +0.0946 (+12.13%)
Streaming Delayed Price Updated: 3:23 PM EDT, Apr 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Waldencast plc - Class A Ordinary Share

< Previous 1 2 3 4 5 6 Next >
News headline image
Waldencast announces conclusion of SEC investigation
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin’s Age and Restore Visible Youthfulness
The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skin 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™
ProMD’s multi-location physician led network will participate in Obagi’s ALOHA Program as part of a structured evaluation of MagIQ and integrated skincare protocols to providers across multiple states 
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast Reports Q4 2025 and FY 2025 Financial Results
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Schweiger Dermatology Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Schweiger selected as a leading dermatology platform partner due to its commitment to clinical excellence, rapid access to care, and dissemination across its extensive national network of practices 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and It’s a Secret Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
It’s a Secret Med Spa selected as a premier luxury med spa partner due to its commitment to excellence, personalized luxury aesthetic experiences, and outstanding patient results across its growing... 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Aesthetic Record Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Aesthetic Record selected as a leading aesthetics EMR and practice management partner due to its commitment to technology innovation, operational efficiency, and supporting thousands of aesthetic... 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
DermFx selected as a leading regional med spa partner due to its commitment to exceptional patient care, aesthetic innovation, and excellence across Southern California practices 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Moxie selected as a leading aesthetic practice software and support partner for its commitment to innovation, compliance, and empowering aesthetic entrepreneurs 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
The dermatologist-tested duo pairs gentle chemical resurfacing with daily hydration and SPF protection for visibly smoother lips 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and VIO Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
VIO Med Spa selected as a key med spa franchise partner for its commitment to clinical excellence, innovation, and nationwide scalable aesthetic care 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Next Health Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Next Health selected as a leading wellness and longevity partner given its innovative approach to personalized aesthetics and health optimization 
From Waldencast plc
Via GlobeNewswire
News headline image
UPDATE - Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
Alpha selected as the first Medspa platform partner given their commitment to innovation, education, and breaking through barriers 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
Alpha selected as the first Medspa platform partner given their commitment to innovation, education, and breaking through barriers 
From Waldencast plc
Via GlobeNewswire
News headline image
CORRECTION – Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Platinum selected as the first dermatology platform partner due to its commitment to clinical evidence and dissemination across its network of practices 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Platinum selected as the first dermatology platform partner due to its commitment to clinical evidence and dissemination across its network of practices 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Unveils ALOHA Program to Launch Obagi® saypha® MagIQ™ – Pioneering the Largest Real-World Evaluation of a New Hyaluronic Acid Filler
Program Designed to Drive Real World, Practice Focused Evidence with Injectables & Skincare 
From Waldencast plc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
From Pomerantz LLP
Via GlobeNewswire
News headline image
Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting
Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation 
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates
First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum
A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair* 
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market 
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation
From Waldencast plc
Via GlobeNewswire
News headline image
Gore Range Capital Announces Sale of Novaestiq Corp. to Waldencast
Via ACCESS Newswire
News headline image
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast Reports Q1 2025 Financial Results
From Waldencast plc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.